CCDC3

Summary

CCDC3 (coiled-coil domain containing 3, HGNC:23813) is a protein-coding gene on chromosome 10p13, encoding Coiled-coil domain-containing protein 3 (Q9BQI4). Negatively regulates TNF-induced pro-inflammatory response in endothelial cells (ECs) via inhibition of TNF-induced NF-kappaB activation in ECs.

Involved in negative regulation of lipid metabolic process; negative regulation of tumor necrosis factor-mediated signaling pathway; and signal transduction. Located in endoplasmic reticulum and extracellular region.

Source: NCBI Gene 83643 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 75 total
• MANE Select transcript: NM_031455

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23813
Approved symbol	CCDC3
Name	coiled-coil domain containing 3
Location	10p13
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp761F241
Ensembl gene	ENSG00000151468
Ensembl biotype	protein_coding
OMIM	620579
Entrez	83643

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000378825, ENST00000378839, ENST00000870347

RefSeq mRNA: 2 — MANE Select: NM_031455 NM_001282658, NM_031455

CCDS: CCDS60484, CCDS7093

Canonical transcript exons

ENST00000378825 — 3 exons

Exon	Start	End
ENSE00001478885	13001197	13001713
ENSE00003633684	12998338	12998512
ENSE00003719066	12896625	12898679

Expression profiles

Bgee: expression breadth ubiquitous, 231 present calls, max score 99.71.

FANTOM5 (CAGE): breadth broad, TPM avg 11.4251 / max 331.0092, expressed in 688 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
108288	10.3547	594
108291	0.2278	93
108285	0.2246	107
205727	0.2062	70
108284	0.1341	54
108290	0.1285	35
108283	0.0831	25
108289	0.0443	15
108287	0.0217	4

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
saphenous vein	UBERON:0007318	99.71	gold quality
right coronary artery	UBERON:0001625	99.48	gold quality
upper arm skin	UBERON:0004263	99.21	gold quality
vena cava	UBERON:0004087	99.17	gold quality
pericardium	UBERON:0002407	99.03	gold quality
coronary artery	UBERON:0001621	98.83	gold quality
left coronary artery	UBERON:0001626	98.74	gold quality
urethra	UBERON:0000057	98.55	gold quality
popliteal artery	UBERON:0002250	98.52	gold quality
tibial artery	UBERON:0007610	98.51	gold quality
descending thoracic aorta	UBERON:0002345	98.42	gold quality
aorta	UBERON:0000947	98.28	gold quality
thoracic aorta	UBERON:0001515	98.00	gold quality
ascending aorta	UBERON:0001496	97.99	gold quality
nipple	UBERON:0002030	97.70	gold quality
penis	UBERON:0000989	97.66	gold quality
calcaneal tendon	UBERON:0003701	97.54	gold quality
skin of hip	UBERON:0001554	97.00	gold quality
upper leg skin	UBERON:0004262	96.15	gold quality
gall bladder	UBERON:0002110	96.14	gold quality
tibial nerve	UBERON:0001323	95.92	gold quality
superficial temporal artery	UBERON:0001614	95.91	gold quality
left uterine tube	UBERON:0001303	95.53	gold quality
tendon	UBERON:0000043	94.91	gold quality
tendon of biceps brachii	UBERON:0008188	94.61	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.59	gold quality
trigeminal ganglion	UBERON:0001675	94.31	gold quality
skin of leg	UBERON:0001511	94.26	gold quality
zone of skin	UBERON:0000014	94.21	gold quality
adipose tissue	UBERON:0001013	94.20	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	47.42
E-GEOD-75367	no	62.26
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

5 targets.

Target	Regulation
CERS1	Repression
CIDEA	Repression
FASN	Repression
HMGCS1	Repression
SREBF1	Repression

Upstream regulators (CollecTRI, top): TP63

miRNA regulators (miRDB)

68 targeting CCDC3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-6505-3P	99.34	67.39	1071
HSA-MIR-6719-3P	99.29	67.78	1387
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-3978	99.24	68.39	2201
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-3940-5P	99.14	65.26	493
HSA-MIR-4507	99.14	65.27	515
HSA-MIR-6768-3P	99.14	67.38	1319
HSA-MIR-4795-5P	99.11	66.90	876

Literature-anchored findings (GeneRIF, showing 4)

• CCDC3 represses TNF-alpha/NF-kappaB-induced pro-inflammatory response in endothelial cells. (PMID:25193116)
• Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from proteasome-mediated degradation. (PMID:36396725)
• CCDC3 Gene Regulates the Proliferation of Breast Cancer Cells. (PMID:37052857)
• Extracellular and intracellular functions of coiled-coil domain containing 3. (PMID:37263799)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccdc3a	ENSDARG00000026052
danio_rerio	ccdc3b	ENSDARG00000030632
mus_musculus	Ccdc3	ENSMUSG00000026676
rattus_norvegicus	Ccdc3	ENSRNOG00000017933

Protein

Protein identifiers

Coiled-coil domain-containing protein 3 — Q9BQI4 (reviewed: Q9BQI4)

Alternative names: Fat/vessel-derived secretory protein

All UniProt accessions (1): Q9BQI4

UniProt curated annotations — full annotation on UniProt →

Function. Negatively regulates TNF-induced pro-inflammatory response in endothelial cells (ECs) via inhibition of TNF-induced NF-kappaB activation in ECs. Positively regulates lipid accumulation in adipose cells.

Subunit / interactions. Homodimer.

Subcellular location. Secreted.

Tissue specificity. Expressed in umbilical vein endothelial cells (HUVEC), and at lower levels in aortic smooth muscle cells (HASMC).

Induction. Up-regulated by pioglitazone and down-regulated by TNF in HUVEC.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BQI4-1	1	yes
Q9BQI4-2	2

RefSeq proteins (2): NP_001269587, NP_113643* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR040311	CCDC3	Family

UniProt features (5 total): signal peptide 1, chain 1, coiled-coil region 1, glycosylation site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BQI4-F1	76.13	0.31

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 100

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 122 (showing top): GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_RESPONSE_TO_PEPTIDE, GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, TERAMOTO_OPN_TARGETS_CLUSTER_6, GOBP_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_LIPID_METABOLIC_PROCESS, chr10p13, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_LIPID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS

GO Biological Process (8): signal transduction (GO:0007165), lipid biosynthetic process (GO:0008610), negative regulation of gene expression (GO:0010629), negative regulation of tumor necrosis factor-mediated signaling pathway (GO:0010804), positive regulation of fat cell differentiation (GO:0045600), negative regulation of lipid metabolic process (GO:0045833), positive regulation of lipid biosynthetic process (GO:0046889), negative regulation of lipid biosynthetic process (GO:0051055)

GO Molecular Function (0):

GO Cellular Component (2): extracellular region (GO:0005576), endoplasmic reticulum (GO:0005783)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lipid metabolic process	2
lipid biosynthetic process	2
regulation of lipid biosynthetic process	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
biosynthetic process	1
gene expression	1
regulation of gene expression	1
negative regulation of macromolecule biosynthetic process	1
negative regulation of cytokine-mediated signaling pathway	1
regulation of tumor necrosis factor-mediated signaling pathway	1
tumor necrosis factor-mediated signaling pathway	1
fat cell differentiation	1
positive regulation of cell differentiation	1
regulation of fat cell differentiation	1
negative regulation of metabolic process	1
regulation of lipid metabolic process	1
positive regulation of biosynthetic process	1
positive regulation of lipid metabolic process	1
negative regulation of biosynthetic process	1
negative regulation of lipid metabolic process	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

606 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC3	PROSER2	Q86WR7	434
CCDC3	CAMK1D	Q8IU85	428
CCDC3	MCUB	Q9NWR8	427
CCDC3	CDC123	O75794	417
CCDC3	KIAA1755	Q5JYT7	409
CCDC3	PGLYRP2	Q96PD5	406
CCDC3	SERTAD4	Q9NUC0	405
CCDC3	GRM7	Q14831	385
CCDC3	NUDT5	Q9UKK9	380
CCDC3	ERICH4	A6NGS2	376
CCDC3	KIRREL3	Q8IZU9	375
CCDC3	DRC2	Q8IXS2	367
CCDC3	CCDC8	Q9H0W5	366
CCDC3	OBSL1	O75147	362
CCDC3	DHTKD1	Q96HY7	349

IntAct

0 interactions, top by confidence:

BioGRID (11): CCDC3 (Affinity Capture-RNA), TP53 (Affinity Capture-Western), CCDC3 (Reconstituted Complex), CCDC3 (Reconstituted Complex), TP53 (Reconstituted Complex), MDM2 (Affinity Capture-Western), MDM2 (Reconstituted Complex), CCDC3 (Co-localization), CCDC3 (Co-localization), CCDC3 (Affinity Capture-Western), PSMC4 (Affinity Capture-Western)

ESM2 similar proteins: A2RT67, A4D0V7, A6NFY4, D2XPP7, O75829, P0CG01, P17404, P54863, P60570, Q1JQA1, Q1RMS8, Q29108, Q2HJB9, Q2KHT6, Q3SZM3, Q3T0J1, Q3TYS2, Q3U128, Q3UX43, Q5R2I8, Q5R2J4, Q5RFG8, Q60GF7, Q62522, Q641X7, Q66KI8, Q6AYA6, Q6DF34, Q6PGD0, Q6Q2W4, Q6UW56, Q7Z6J8, Q7Z7H3, Q8CHQ0, Q8J025, Q8N6S4, Q8TCJ0, Q91Z62, Q969P5, Q99LV7

Diamond homologs: Q9BQI4, Q9D6Y1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

75 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

855 predictions. Top by Δscore:

Variant	Effect	Δscore
10:12898675:ATGAG:A	acceptor_gain	1.0000
10:12898676:TGAG:T	acceptor_gain	1.0000
10:12898677:GAG:G	acceptor_gain	1.0000
10:12898678:AG:A	acceptor_gain	1.0000
10:12898678:AGC:A	acceptor_loss	1.0000
10:12898680:C:CC	acceptor_gain	1.0000
10:12898687:C:CT	acceptor_gain	1.0000
10:12898697:G:C	acceptor_gain	1.0000
10:12998336:AC:A	donor_gain	1.0000
10:12998337:CC:C	donor_gain	1.0000
10:12998337:CCCTA:C	donor_gain	1.0000
10:12998512:CCTAA:C	acceptor_gain	1.0000
10:13001192:CTCA:C	donor_loss	1.0000
10:13001196:C:CT	donor_loss	1.0000
10:12898688:A:T	acceptor_gain	0.9900
10:12898693:CAGCG:C	acceptor_gain	0.9900
10:12898694:A:T	acceptor_gain	0.9900
10:12898696:CG:C	acceptor_gain	0.9900
10:12898697:G:GC	acceptor_gain	0.9900
10:12998332:TCTTA:T	donor_loss	0.9900
10:12998333:CTTA:C	donor_loss	0.9900
10:12998334:TTA:T	donor_loss	0.9900
10:12998335:TACC:T	donor_loss	0.9900
10:12998336:A:AT	donor_loss	0.9900
10:12998337:C:A	donor_loss	0.9900
10:12998348:T:TA	donor_gain	0.9900
10:12998430:T:TA	donor_gain	0.9900
10:12998508:CCATC:C	acceptor_gain	0.9900
10:12998509:CATC:C	acceptor_gain	0.9900
10:12998509:CATCC:C	acceptor_gain	0.9900

AlphaMissense

1756 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:12998426:A:C	F154C	0.999
10:12998426:A:G	F154S	0.999
10:12998473:A:C	N138K	0.999
10:12998473:A:T	N138K	0.999
10:13001323:C:G	C83S	0.999
10:13001324:A:T	C83S	0.999
10:13001487:C:A	W28C	0.999
10:13001487:C:G	W28C	0.999
10:12998456:A:C	F144C	0.998
10:13001310:C:A	W87C	0.998
10:13001310:C:G	W87C	0.998
10:13001323:C:T	C83Y	0.998
10:13001324:A:G	C83R	0.998
10:13001341:G:T	A77D	0.998
10:13001434:G:T	A46D	0.998
10:12998408:A:C	F160C	0.997
10:12998486:G:T	P134H	0.997
10:13001322:G:C	C83W	0.997
10:13001323:C:A	C83F	0.997
10:13001443:A:T	I43N	0.997
10:12898671:G:C	C186W	0.996
10:12898672:C:G	C186S	0.996
10:12898673:A:T	C186S	0.996
10:12998407:A:C	F160L	0.996
10:12998407:A:T	F160L	0.996
10:12998409:A:G	F160L	0.996
10:12998425:A:C	F154L	0.996
10:12998425:A:T	F154L	0.996
10:12998427:A:G	F154L	0.996
10:12998456:A:G	F144S	0.996

dbSNP variants (sampled 300 via entrez): RS1000022001 (10:12988578 G>A), RS1000033330 (10:12949092 T>C), RS1000053204 (10:12920328 C>A,T), RS1000053917 (10:12904591 T>C), RS1000058833 (10:13025852 A>C), RS1000075422 (10:13096930 G>A,T), RS1000084630 (10:13007866 T>A), RS1000109008 (10:12985232 C>T), RS1000109010 (10:12925546 C>A), RS1000113274 (10:13019853 C>A,T), RS1000114027 (10:13099974 C>T), RS1000123905 (10:13042256 C>T), RS1000140986 (10:13010970 A>G), RS1000143039 (10:13064159 C>T), RS1000161338 (10:13048163 A>G,T)

Disease associations

OMIM: gene MIM:620579 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): lip and oral cavity carcinoma (MONDO:0023644)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST000817_133	Height	3.000000e-09
GCST006998_5	Cerebrospinal fluid p-tau levels in mild cognitive impairment	5.000000e-08
GCST007008_4	Cerebrospinal fluid p-tau levels	4.000000e-06
GCST007401_15	Factor VII activity	2.000000e-06
GCST008163_136	Height	8.000000e-06
GCST008163_470	Height	5.000000e-07
GCST008839_125	Height	3.000000e-32
GCST010219_13	Attention deficit hyperactivity disorder (inattention symptoms)	3.000000e-07
GCST012226_103	Waist circumference adjusted for body mass index	3.000000e-08
GCST012226_104	Waist circumference adjusted for body mass index	9.000000e-11
GCST012226_328	Waist circumference adjusted for body mass index	2.000000e-08
GCST012226_329	Waist circumference adjusted for body mass index	5.000000e-10
GCST012227_454	Hip circumference adjusted for BMI	6.000000e-09
GCST90000025_392	Appendicular lean mass	6.000000e-12

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004760	t-tau measurement
EFO:0004763	p-tau measurement
EFO:0004619	factor VII measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0008039	BMI-adjusted hip circumference
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	8
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	increases expression	3
Tretinoin	decreases expression	3
Vorinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Doxorubicin	increases expression	2
Estradiol	increases expression, decreases expression, affects cotreatment	2
Silicon Dioxide	decreases expression, increases expression	2
Aflatoxin B1	decreases expression, increases methylation	2
propionaldehyde	increases expression	1
sodium arsenate	decreases expression, increases abundance	1
trimellitic anhydride	decreases expression	1
sulforaphane	decreases expression	1
butyraldehyde	increases expression	1
nickel sulfate	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
pentanal	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, decreases methylation	1
jinfukang	increases expression, affects cotreatment	1
Fulvestrant	affects cotreatment, decreases methylation	1
Aldehydes	increases expression	1
Arsenic	decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

211 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01418118	PHASE4	COMPLETED	Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
NCT03017053	PHASE4	UNKNOWN	The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor
NCT03684707	PHASE4	UNKNOWN	Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
NCT00158652	PHASE3	COMPLETED	Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC
NCT00158678	PHASE3	COMPLETED	IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
NCT00402779	PHASE3	COMPLETED	Erlotinib Prevention of Oral Cancer (EPOC)
NCT00655421	PHASE3	UNKNOWN	Oral Cancer Screening in Mumbai, India by Primary Health Care Workers
NCT00750503	PHASE3	COMPLETED	Workplace Tobacco Cessation And Oral Cancer Screening Study
NCT00964977	PHASE3	COMPLETED	Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
NCT01039298	PHASE3	UNKNOWN	Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL
NCT03685409	PHASE3	UNKNOWN	Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
NCT05721755	PHASE3	ACTIVE_NOT_RECRUITING	Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT06589804	PHASE3	RECRUITING	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06737822	PHASE3	RECRUITING	Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:
NCT07402538	PHASE3	NOT_YET_RECRUITING	Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma
NCT07441681	PHASE3	NOT_YET_RECRUITING	Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NCT00330382	PHASE2	COMPLETED	Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
NCT00400205	PHASE2	TERMINATED	Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil
NCT00933387	PHASE2	COMPLETED	A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
NCT01440270	PHASE2	COMPLETED	Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
NCT01733797	PHASE2	COMPLETED	Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients
NCT02734537	PHASE2	RECRUITING	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02960724	PHASE2	UNKNOWN	uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
NCT03008694	PHASE2	UNKNOWN	Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients
NCT03174275	PHASE2	ACTIVE_NOT_RECRUITING	Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
NCT03383094	PHASE2	ACTIVE_NOT_RECRUITING	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
NCT03529422	PHASE2	ACTIVE_NOT_RECRUITING	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
NCT04191460	PHASE2	RECRUITING	Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
NCT04251949	PHASE2	COMPLETED	Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis.
NCT04541355	PHASE2	COMPLETED	Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
NCT04862650	PHASE2	ACTIVE_NOT_RECRUITING	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05136196	PHASE2	RECRUITING	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05172258	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05456022	PHASE2	UNKNOWN	Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
NCT05941338	PHASE2	RECRUITING	Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
NCT05980702	PHASE2	RECRUITING	4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
NCT06084845	PHASE2	WITHDRAWN	Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
NCT06130332	PHASE2	RECRUITING	Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
NCT06532279	PHASE2	RECRUITING	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT06627270	PHASE2	RECRUITING	Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer